Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.40 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020758 | 0.83 | NOTUM (0.53) | NOTUMKDRMAPTLMNAGAA | |
| SCHEMBL3018822 | 0.81 | NOTUM (0.56) | NOTUMKDRMAPTLMNAGRM4 | |
| SCHEMBL14192684 | 0.80 | KDR (0.42) | KDRMAPTLMNAGAARAB9A | |
| SCHEMBL1789556 | 0.75 | KDR (0.47) | KDRMAPTLMNAGAARAB9A | |
| SCHEMBL1792940 | 0.75 | NOTUM (0.46) | NOTUMMAPTLMNAGAAGRM4 | |
| SCHEMBL1791221 | 0.75 | MAPT (0.54) | KDRMAPTLMNARAB9ATRPV1 | |
| SCHEMBL1794021 | 0.73 | TP53 (0.67) | NOTUMMAPTRAB9AALDH1A1MEN1 | |
| SCHEMBL1791580 | 0.72 | NOTUM (0.56) | NOTUMKDRRAB9ATRPV1ALDH1A1 | |
| SCHEMBL15677832 | 0.72 | NOTUM (0.53) | NOTUMKDRMAPTLMNAGAA | |
| SCHEMBL1789620 | 0.72 | MAPT (0.47) | NOTUMKDRMAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8481001-B2 | Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer | EXELIXIS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | NOTUM 4368/4885KDR 2390/4885MAPT 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.